Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib
https://doi.org/10.47360/1995-4484-2020-420-427
Abstract
Modern therapy for rheumatoid arthritis (RA) allows not only to reduce the activity of immune-mediated inflammation and slow down the progression of the disease, but also to quickly eliminate the main symptoms that cause the most concern to patients, such as pain, functional disorders, fatigue. This action has an inhibitor of Janus kinases 1/ 2 – baricitinib, which quickly reduces the activity of inflammation, provides remission in RA, and has a high analgesic effect. The review discusses the role of autoimmune inflammation and the intracellular signaling pathway JAK/STAT (Janus kinase/signal transducers and activators of transcription) in the pathogenesis of chronic pain in RA, the role of baricitinib for effective control of pain intensity and fatigue.
About the Author
A. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Smolen J, Aletaha D, Barton A, et al. Rheumatoid Arthritis. Nat Rev Dis Primers. 2018;4:18001. Published 2018 Feb 8. doi:10.1038/nrdp.2018.1
2. Nasonov EL, Olyunin YA, Lila AM. Rheumatoid arthritis: the problems of remission and therapy resistance/ Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2018; 56(3):263-271. (In Russ.). https://doi.org/10.14412/1995-4484-2018-263-271
3. Nasonov EL. Pharmacotherapy for rheumatoid arthritis: new strategy, new targets. Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2017;55(4):409-419. (In Russ.). Doi:10.14412/1995-4484-2017-409-419
4. Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. J Clin Med. 2019; 8(7):938. doi: 10.3390/jcm8070938
5. Burmester G, Bijlsma J, Cutolo M, McInnes I. Managing Rheumatic and Musculoskeletal Diseases – Past, Present and Future. Nat Rev Rheumatol. 2017; 13(7):443-448. doi: 10.1038/nrrheum.2017.95
6. Van Tuyl LH, Michaud K. Patient-Reported Outcomes in Rheumatoid Arthritis. Rheum Dis Clin North Am. 2016; 42(2):219-37. doi: 10.1016/j.rdc.2016.01.010
7. Fautrel B, Alten R, Kirkham B, et al. Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int. 2018; 38(6):935-947. doi: 10.1007/s00296-018-4005-5
8. Smolen JS, Strand V, Koenig AS, Szumski A, Kotak S, Jones TV. Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Res Ther. 2016; 18(1):114. doi: 10.1186/s13075-016-1004-3
9. Zhang A, Lee YC. Mechanisms for Joint Pain in Rheumatoid Arthritis (RA): from Cytokines to Central Sensitization. Curr Osteoporos Rep. 2018;16(5):603-610. doi: 10.1007/s11914-018-0473-5
10. Sharma J, Bhar S, Devi CS. A review on interleukins: The key manipulators in rheumatoid arthritis. Mod Rheumatol. 2017; 27(5):723-746. doi: 10.1080/14397595.2016.1266071
11. Ge C, Holmdahl R. The structure, specificity and function of anti-citrullinated protein antibodies. Nat Rev Rheumatol. 2019;15(8):503-508. doi: 10.1038/s41584-019-0244-4
12. Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing Receptors in Sterile Inflammation and Inflammatory Diseases. Nat Rev Immunol. 2020; 20(2):95-112. doi: 10.1038/s41577-019-0215-7
13. Takeuchi Y, Hirota K, Sakaguch S. Synovial Tissue Inflammation Mediated by Autoimmune T Cells. Front Immunol. 2019;10:1989. doi: 10.3389/fimmu.2019.01989.
14. Nagata S. Apoptosis and Clearance of Apoptotic Cells. Annu Rev Immunol. 2018 Apr 26;36:489-517. doi: 10.1146/annurev-immunol-042617-053010
15. Smith Jr T, Tharakan A, Martin R. Targeting ADAM10 in Cancer and Autoimmunity. Front Immunol. 2020; 11:499. doi: 10.3389/fimmu.2020.00499
16. Deane K, Holers V. The Natural History of Rheumatoid Arthritis. Clin Ther. 2019;41(7):1256-1269. doi: 10.1016/j.clinthera.2019.04.028
17. Uciechowski P, Dempke W. Interleukin-6: A Masterplayer in the Cytokine Network. Oncology. 2020; 98(3):131-137. doi: 10.1159/000505099
18. Crotti C, Agape E, Becciolini A, Biggioggero M, Favalli EG. Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. Drugs. 2019; 79(16):1741-1755. doi: 10.1007/s40265-019-01192-z
19. Katz EJ, Gold MS. Inflammatory hyperalgesia: a role for the C-fiber sensory neuron cell body? J Pain. 2006; 7(3):170-8. doi: 10.1016/j.jpain.2005.10.003
20. Chen X, Alessandri-Haber N, Levine JD. Marked attenuation of inflammatory mediator-induced C-fiber sensitization for mechanical and hypotonic stimuli in TRPV4-/- mice. Mol Pain. 2007; 3:31. doi: 10.1186/1744-8069-3-31
21. Lee C-H, Giuliani F. The Role of Inflammation in Depression and Fatigue. Front Immunol. 2019 Jul 19;10:1696. doi: 10.3389/fimmu.2019.01696
22. Kim K-H, Seo H-J, Abdi S., Huh B. All About Pain Pharmacology: What Pain Physicians Should Know. Korean J Pain. 2020;33(2):108-120. doi: 10.3344/kjp.2020.33.2.108
23. Harth M, Nielson WR. Pain and affective distress in arthritis: relationship to immunity and inflammation. Expert Rev Clin Immunol. 2019; 15(5):541-552. doi: 10.1080/1744666X.2019.1573675
24. Yang S, Chang M. Chronic Pain: Structural and Functional Changes in Brain Structures and Associated Negative Affective States. Int J Mol Sci. 2019; 20(13):3130. doi: 10.3390/ijms20133130
25. Zhao SS, Duffield SJ, Goodson NJ. The prevalence and impact of comorbid fibromyalgia in inflammatory arthritis. Best Pract Res Clin Rheumatol. 2019;33(3):101423. doi: 10.1016/j.berh.2019.06.005
26. Dougados M, Perrot S. Fibromyalgia and central sensitization in chronic inflammatory joint diseases. Joint Bone Spine. 2017; 84(5):511-513. doi: 10.1016/j.jbspin.2017.03.001
27. Druce KL, Basu N. Predictors of fatigue in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 5): v29-v34. doi: 10.1093/rheumatology/kez346
28. Daviu N, Bruchas M, Moghaddam B, Sandi C, Beyeler A. Neurobiological Links Between Stress and Anxiety. Neurobiol Stress. 2019; 11:100191. doi: 10.1016/j.ynstr.2019.100191.
29. Maloley PM, England BR, Sayles H, et al. Post-traumatic stress disorder and serum cytokine and chemokine concentrations in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019; 49(2):229-235. doi: 10.1016/j.semarthrit.2019.02.002
30. Tiosano S, Yavne Y, Watad A, et al. The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis.Eur J Clin Invest. 2020 Jun 1:e13268. doi: 10.1111/eci.13268
31. Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018;22(2):216-241. doi: 10.1002/ejp.1140
32. Kaplan C, Minc A, Basu N, Schrepf A. Inflammation and the Central Nervous System in Inflammatory Rheumatic Disease. Curr Rheumatol Rep. 2019;21(12):67. doi: 10.1007/s11926-019-0870-5
33. Kiguchi N, Kobayashi D, Saika F, Matsuzaki S, Kishioka S. Pharmacological Regulation of Neuropathic Pain Driven by Inflammatory Macrophages. Int J Mol Sci. 2017;18(11):2296. doi: 10.3390/ijms18112296
34. Siouti E, Andreakos E. The many facets of macrophages in rheumatoid arthritis. Biochem Pharmacol. 2019;165:152-169. doi: 10.1016/j.bcp.2019.03.029
35. Kothari P, Pestana R, Mesraoua R, et al. IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAKdependent IL-10 expression in macrophages. J Immunol. 2014;192(1):349-57. doi: 10.4049/jimmunol.1301906
36. Salaffi F, Giacobazzi G, Di Carlo M. Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway. Pain Res Manag. 2018;2018:8564215
37. Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2019;57(1):8-16. (In Russ.). doi:10.14412/1995-4484-2019-8-16.
38. Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33(1):15-32. doi: 10.1007/s40259-019-00333-w
39. Park SJ, Lee JH, Kim HY, et al. Astrocytes, but not microglia, rapidly sense H₂O₂via STAT6 phosphorylation, resulting in cyclooxygenase-2 expression and prostaglandin release. J Immunol. 2012;188(10):5132-5141. doi:10.4049/jimmunol.1101600
40. Ding CP, Guo YJ, Li HN, et al. Red nucleus interleukin-6 participates in the maintenance of neuropathic pain through JAK/ STAT3 and ERK signaling pathways. Exp Neurol. 2018 Feb;300:212-221. DOI: 10.1016/j.expneurol.2017.11.012
41. Xu Z, Wu H, Zhang H, Bai J, Zhang Z. Interleukins 6/8 and cyclooxygenase-2 Release and Expressions Are Regulated by Oxidative stress-JAK2/STAT3 Signaling Pathway in Human Bronchial Epithelial Cells Exposed to Particulate Matter ≤2.5 μm. J Appl Toxicol. 2020 Mar 24. doi: 10.1002/jat.3977
42. Choy EHS, Miceli-Richard C, González-Gay MA, et al. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clin Exp Rheumatol. 2019;37(4):694- 704
43. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655
44. Nasonov EL, Lila AM. Baricitinib: new pharmacotherapy options for rheumatoid arthritis and other immune-mediated inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2020;58(3):304-316. (In Russ.). doi:10.14412/1995-4484-2020-304-316
45. Pope J, Sawant R, Tundia N, et al. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Adv Ther. 2020;37(5):2356-2372. doi: 10.1007/s12325-020-01303-3
46. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652-662. doi: 10.1056/NEJMoa1608345
47. Keystone EC, Taylor PC, Tanaka Y., et al. Patient-reported Outcomes From a Phase 3 Study of Baricitinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: Secondary Analyses From the RA-BEAM Study. Ann Rheum Dis. 2017;76(11):1853-1861. doi: 10.1136/annrheumdis-2017-211259
48. Taylor PC, Lee YC, Fleischmann R, et al. Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. J Clin Med. 2019;8(6). pii: E831. doi: 10.3390/jcm8060831
49. Smolen JS, Kremer JM, Gaich CL, et al. Patient-reported Outcomes From a Randomised Phase III Study of Baricitinib in Patients With Rheumatoid Arthritis and an Inadequate Response to Biological Agents (RA-BEACON). Ann Rheum Dis. 2017;76(4):694-700. doi: 10.1136/annrheumdis-2016-209821
50. Fautrel B, Zhu B, Taylor PC, et al. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison. RMD Open. 2020;6(1). pii: e001131. doi: 10.1136/rmdopen-2019-001131
Review
For citations:
Karateev A.E. Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib. Rheumatology Science and Practice. 2020;58(4):420-427. (In Russ.) https://doi.org/10.47360/1995-4484-2020-420-427
Views:
2262
Email this article 